Journal article
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
Abstract
Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate the cost-effectiveness of denosumab in a Swedish setting, also accounting for poor adherence to treatment. Denosumab is cost-effective, particularly for patients at high risk of fracture and low adherence to oral treatments.IntroductionDenosumab is a novel biologic agent developed for the treatment of osteoporosis and osteoporotic fractures that …
Authors
Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Journal
Osteoporosis International, Vol. 22, No. 3, pp. 967–982
Publisher
Springer Nature
Publication Date
March 2011
DOI
10.1007/s00198-010-1424-x
ISSN
0937-941X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAlendronateAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBone Density Conservation AgentsCohort StudiesCost-Benefit AnalysisDenosumabEtidronic AcidFemaleHumansMarkov ChainsMiddle AgedOrganometallic CompoundsOsteoporosis, PostmenopausalOsteoporotic FracturesPatient ComplianceQuality-Adjusted Life YearsRANK LigandRisedronic AcidThiophenes